These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 11251358)

  • 1. Does low-molecular-weight heparin reduce the costs of venous thromboembolism treatment?
    Bossuyt PM; Prins MH
    Haemostasis; 2000; 30 Suppl 2():136-40; discussion 128-9. PubMed ID: 11251358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
    Gould MK; Dembitzer AD; Sanders GD; Garber AM
    Ann Intern Med; 1999 May; 130(10):789-99. PubMed ID: 10366368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
    Huse DM; Cummins G; Taylor DC; Russell MW
    Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis.
    O'Brien B; Levine M; Willan A; Goeree R; Haley S; Blackhouse G; Gent M
    Arch Intern Med; 1999 Oct; 159(19):2298-304. PubMed ID: 10547169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.
    Knight KK; Wong J; Hauch O; Wygant G; Aguilar D; Ofman JJ
    Value Health; 2005; 8(3):191-200. PubMed ID: 15877591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct medical cost of managing deep vein thrombosis according to the occurrence of complications.
    O'Brien JA; Caro JJ
    Pharmacoeconomics; 2002; 20(9):603-15. PubMed ID: 12141888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of low-molecular-weight heparin in the treatment of proximal deep vein thrombosis.
    Estrada CA; Mansfield CJ; Heudebert GR
    J Gen Intern Med; 2000 Feb; 15(2):108-15. PubMed ID: 10672114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.
    Rodger M; Bredeson C; Wells PS; Beck J; Kearns B; Huebsch LB
    CMAJ; 1998 Oct; 159(8):931-8. PubMed ID: 9834718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economics of low-molecular weight heparins.
    Rutschmann OT; Matchar DB
    Am J Manag Care; 2000 Nov; 6(20 Suppl):S1054-65; quiz 1066-7. PubMed ID: 11484305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Out-of-hospital treatment of venous thrombosis: socioeconomic aspects and patients' quality of life.
    Bossuyt PM; van den Belt AG; Prins MH
    Haemostasis; 1998; 28 Suppl 3():100-7. PubMed ID: 10069769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
    Avritscher EB; Cantor SB; Shih YC; Escalante CP; Rivera E; Elting LS
    Support Care Cancer; 2004 Jul; 12(7):531-6. PubMed ID: 14986076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboprophylaxis with low-molecular-weight heparin: economic considerations.
    Mätzsch T
    Haemostasis; 2000; 30 Suppl 2():141-5; discussion 128-9. PubMed ID: 11251359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement.
    Bergqvist D; Jönsson B
    Haemostasis; 2000; 30 Suppl 2():130-5; discussion 128-9. PubMed ID: 11251357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.
    Fowler RA; Mittmann N; Geerts W; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    JAMA; 2014 Nov; 312(20):2135-45. PubMed ID: 25362228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.
    Hull RD
    Thromb Haemost; 2008 Mar; 99(3):502-10. PubMed ID: 18327398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
    Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
    J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of low molecular weight heparin in the initial management of patients with deep vein thrombosis.
    Betten KC
    J Am Acad Nurse Pract; 2000 Jul; 12(7):267-72. PubMed ID: 11930465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.